Vertex Pharmaceuticals Inc. announced today that it submitted a New Drug Application to the U.S. Food and Drug Administration for the approval of the first triple-combination therapy for cystic fibrosis.
Today, Vertex Pharmaceuticals Inc. released the initial Phase 3 clinical trial data for one of two next-generation, triple-combination modulators currently being tested.
Phase 2 clinical trial results were announced today for a potential next-generation modulator to treat people with two copies of the most common cystic fibrosis mutation, F508del.
A new drug intended to make it easier to clear mucus from the lungs of people with cystic fibrosis showed promising results in a Phase 2 clinical trial. The drug, called SPX-101, blocks the overactive sodium channels that line CF lung cells.
Today Vertex Pharmaceuticals Inc. announced the two next-generation CFTR modulator candidates that will progress into Phase 3 clinical trials.
The Cystic Fibrosis Foundation is offering two vital resources to support CF families who may be affected by Hurricane Michael.
In the wake of Hurricane Florence, the Cystic Fibrosis Foundation is offering two vital resources to support CF families affected by this hurricane and its surge.
Yesterday, President Donald J. Trump signed the Right to Try bill into law. The House approved the bill last week and the Senate passed it last summer.
In the aftermath of Hurricane Harvey and Hurricane Irma, the Cystic Fibrosis Foundation has provided the following resources. Our Compass team continues to stand by and offer support of those impacted by these storms.